Navigation Links
International Isotopes Inc. Announces Second Quarter and Six Months 2009 Financial Results
Date:8/12/2009

0, 2009 were $519,034 as compared to $507,865 for the same period in 2008 and $1,055,088 for the six month period ended June 30, 2009 as compared to $1,020,477 for the same six month period of 2008. General administrative expenses totaled $457,873 for the three-month period ended June 30, 2009 as compared to $663,415 for the same period of 2008 and $889,514 for the six month period ended June 30, 2009, as compared to $1,280,582 same period of 2008.

Net Loss: Our net loss for the three and six-month periods ended June 30, 2009 was $758,634 and $1,346,561 respectively compared to a loss of $246,710 and $712,654 for the same periods in 2008. This is an increase in loss of $511,924 for the three-months ended June 30, 2008 and an increase in loss of $633,907 for the six months ended June 30, 2009, and was attributable to research and development costs related to the depleted uranium de-conversion and fluorine extraction processing facility.

Steve T. Laflin, President and CEO of International Isotopes Inc. said, "With the exception of our Radiological Services, all of our business segments continue to grow or at least sustain the levels we achieved in 2008.

"The Radiological Services segment has been clearly impacted by the struggling world economy but we do not expect any similar impact on our other business segments. In fact, I remain quite optimistic about our future performance in these business segments because we anticipate new sales and market growth opportunities for our isotopes. These opportunities are caused in part by interruptions in supply from some of our competitors. Those interruptions have been caused by reduced or limited operability of some isotope producing reactors in the world. We, on the other hand, have a stable operating reactor source for our cobalt products. Additionally, we have agreements in place with other operating reactors for the other products we supply. We belie
'/>"/>

SOURCE International Isotopes Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results
2. HeartWare International, Inc. Announces US$55 Million Financing
3. FoodBizDaily.com Announces New Free Report - International Trade Opportunity: The Brazilian Acai Berry
4. Urgent Petition Launched to Block Plans for New International Late-Term Abortion Clinic
5. Chindex International, Inc. Reports First Quarter Fiscal 2010 Financial Results
6. Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products
7. Chindex International, Inc. Launches World-Class Cancer Treatment Center
8. EHE International Supports The Michael J. Fox Foundation for Parkinsons Research
9. International meeting on food quality, safety
10. BD and Direct Relief International Team Up to Provide Free Diabetes Insulin Injection Products to Americans Impacted by the Economic Downturn
11. Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Healthcare leaders will gather at the ... Walt Disney World Swan and Dolphin in Orlando, Fla., ... care delivery and healthcare reform and implementation. , “Reform ... markets, with consolidation, efficiency and reduced payments ... Ebert, Amerinet president and CEO. “There is a real ...
(Date:5/19/2013)... People in Minnesota have a great option to get ... 28 Day Fat Loss Formula. The best part is ... own home. The product sells for $135 dollars and is ... here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is almost here. ... after using the 28 Day Fat Loss Formula they will ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Actos ... federal litigation now underway in U.S. District Court, Western ... Order dated May 3rd, the Court has modified the ... to eight cases rather than four. The next Status ... Thursday, May 23rd. (In re: Actos Product Liability Litigation, ...
(Date:5/19/2013)... Park City, Utah (PRWEB) May 19, 2013 ... new information on small business health insurance ... alternatives to traditional employer sponsored health benefits, is ... contribution and health reimbursement arrangements . ... businesses, start-ups, and the self-employed intrinsically know the ...
(Date:5/19/2013)... According to a new market research report "Image ... By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), Surveillance, Automobile, ... Infrared, X-Ray) And Geography" published by MarketsandMarkets, the ... in 2012 and is expected to reach $10.75 ... 3.84% from 2013 to 2018. In terms of ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3
... 21 (HealthDay News) -- The frequency of diabetic kidney disease ... the United States over the past two decades, a new ... develop diabetic kidney disease (DKD), which is a leading cause ... all new cases of kidney failure in the United States, ...
... prostate cancer and who are also smokers have an ... death, according to a study in the June 22/29 ... an increased likelihood of prostate cancer recurrence. Accumulating ... prostate cancer and prostate cancer mortality. However, studies of ...
... from around the world will gather in Cincinnati ... management of vasospasm, a dreaded, life-threatening complication of ... They hope to generate the first set of ... patients who have suffered a subarachnoid hemorrhage, or ...
... Only 11 percent of patients who experience a potentially deadly ... to another hospital for procedures such as balloon angioplasty or ... minutes. Instead, a new study finds the average time ... delay that researchers say may increase the risk of death. ...
... TUESDAY, June 21 (HealthDay News) -- Smokers diagnosed with prostate ... treatment and are more likely to die than non-smokers, a ... the Health Professionals Follow-Up Study who were diagnosed with prostate ... this group of men, including 524 (32 percent) from prostate ...
... of scientists led by researchers at the University of California, ... cells (iPSCs) derived from patients with amyotrophic lateral sclerosis (ALS) ... a specific protein may play a central role in causing ... work, published in the June 2011 online issue of the ...
Cached Medicine News:Health News:Diabetic Kidney Disease Rising in the U.S. 2Health News:Being a smoker at time of prostate cancer diagnosis linked with increased risk of death 2Health News:International Vasospasm 2011 conference could be springboard for treatment guidelines 2Health News:International Vasospasm 2011 conference could be springboard for treatment guidelines 3Health News:Delays in Hospital Transfers for Heart Attack Patients May Raise Death Risk 2Health News:Smoking, Prostate Cancer a Deadly Mix 2Health News:Stem cell model offers clues to cause of inherited ALS 2
(Date:5/17/2013)... CHAPEL HILL, N.C. , May 17, 2013 ... on how organizations communicate internally. Faced with a ... adjust their strategies and tactics for communicating with ... the effectiveness of all the strategies, tactics and ... In a new study, Best ...
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology ... Sony SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting ... which will be held at the San ... Diego, California , from May 20 - 22.  ... second analytical system, incorporating commercial audio-visual technologies into new ...
(Date:5/17/2013)... May 17, 2013  TechAtlas Group has announced ... competitive landscape map for the Chronic Kidney Disease ... international companies with drugs and devices currently on ... its sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... , hypertension - renal denervation , diabetic ...
Breaking Medicine Technology:Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... , , BENLYSTA ... TRIALS , , ... (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical ... the lupus patients who were treated with BENLYSTA had improvement in ...
... , , , ... Genome Sciences, Inc. (Nasdaq: HGSI ) and GlaxoSmithKline ... the primary endpoint in BLISS-52, the first of two pivotal ... erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results ...
Cached Medicine Technology:First Potential Lupus-Specific Treatment in Sight 2First Potential Lupus-Specific Treatment in Sight 3Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 2Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 3Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 4Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 5Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 6Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 7Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 8Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 9Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus 10
... external computer-enhanced microplate reader with ... automated flexible and rapid photometric ... accurate and reliable photometric measurement ... without shaking before reading) and ...
... combine a number of assay steps ... a simple to use benchtop device. ... multifunctional stand-alone device but also provides ... Custom and standard add-on modules provide ...
... Micro Plate Processor is a precise, ... Analyzer. It has been designed for ... can be customised according to the ... Processor is able to process automatically ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Medicine Products: